GNRHR and ovarian carcinoma: In ovarian cancer cell lines EFO-21 and EFO-27 that express GnRH and GnRH-R, treatment with GnRH-agonist triptorelin (100 nM) resulted in an increase of cells in the G0/1 phase of the cell cycle and a decrease in the G2/s phase.